ProCE Banner Activity

SORMAIN: Sorafenib vs Placebo Maintenance Therapy After Allogeneic SCT in FLT3-ITD AML

Slideset Download
Conference Coverage
Sorafenib maintenance therapy after transplantation significantly reduced the disease relapse rate and improved survival compared with placebo in patients with FLT3-ITD AML.

Released: December 10, 2018

Expiration: December 09, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology